{"organizations": [], "uuid": "428d4a9c44027208d898de82a6f1f352608a32c5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180123.html", "section_title": "Archive News &amp; Video for Tuesday, 23 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-shanghai-fudan-zhangjiang-bio-phar/brief-shanghai-fudan-zhangjiang-bio-pharmaceutical-expects-to-record-a-decrease-in-fy-net-profit-idUSFWN1PI0D2", "country": "US", "domain_rank": 408, "title": "BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ‍Expects To Record A Decrease In FY Net Profit", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.977, "site_type": "news", "published": "2018-01-23T18:06:00.000+02:00", "replies_count": 0, "uuid": "428d4a9c44027208d898de82a6f1f352608a32c5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-shanghai-fudan-zhangjiang-bio-phar/brief-shanghai-fudan-zhangjiang-bio-pharmaceutical-expects-to-record-a-decrease-in-fy-net-profit-idUSFWN1PI0D2", "ord_in_thread": 0, "title": "BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ‍Expects To Record A Decrease In FY Net Profit", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "shanghai fudan-zhangjiang bio-pharmaceutical co ltd", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 23 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:\n* ‍EXPECTS TO RECORD A DECREASE IN NET PROFIT OF GROUP BY APPROXIMATELY 50% FOR FY\n* ‍EXPECTS DECREASE IN FY REVENUE OF GROUP BY APPROXIMATELY 20%\n* EXPECTED DECREASE IN REVENUE DUE TO DECREASED REVENUE FROM LIBOD BY ABOUT 50% FOR FY ENDED 31 DEC 2017​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-23T18:06:00.000+02:00", "crawled": "2018-01-24T15:44:06.006+02:00", "highlightTitle": ""}